Hapvida Participações e Investimentos S.A.

BASE:HAPV3 Stock Report

Market Cap: AR$3.0t

Hapvida Participações e Investimentos Past Earnings Performance

Past criteria checks 0/6

Hapvida Participações e Investimentos's earnings have been declining at an average annual rate of -60.5%, while the Healthcare industry saw earnings growing at 16.8% annually. Revenues have been growing at an average rate of 31.9% per year.

Key information

-60.5%

Earnings growth rate

-61.2%

EPS growth rate

Healthcare Industry Growth36.3%
Revenue growth rate31.9%
Return on equity-1.1%
Net Margin-2.0%
Next Earnings Update20 Mar 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Hapvida Participações e Investimentos makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BASE:HAPV3 Revenue, expenses and earnings (BRL Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2427,326-5361,6420
30 Jun 2427,335-5551,4100
31 Mar 2427,976-4611,4010
31 Dec 2327,770-7591,5430
30 Sep 239,971-1,885-1,2820
30 Jun 2315,080-1,7512140
31 Mar 2320,085-1,7761,3360
31 Dec 2223,812-1,7202,0040
30 Sep 2219,845-2615,1770
30 Jun 2216,083-2524,0490
31 Mar 2212,4021663,0790
31 Dec 219,8834982,5540
30 Sep 219,5583892,4510
30 Jun 219,1255952,3070
31 Mar 218,7997692,1630
31 Dec 208,5557832,0710
30 Sep 208,0679011,7690
30 Jun 207,2568651,5900
31 Mar 206,4568091,3290
31 Dec 195,6348501,1180
30 Sep 195,0608759820
30 Jun 194,9088528980
31 Mar 194,4117148520
31 Dec 184,5767879510
30 Sep 184,4081,2018350
31 Mar 184,3837687960
31 Dec 173,8486498050
31 Dec 163,0364576800
31 Dec 152,4593016170
31 Dec 141,9642704370

Quality Earnings: HAPV3 is currently unprofitable.

Growing Profit Margin: HAPV3 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: HAPV3 is unprofitable, and losses have increased over the past 5 years at a rate of 60.5% per year.

Accelerating Growth: Unable to compare HAPV3's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HAPV3 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (15.6%).


Return on Equity

High ROE: HAPV3 has a negative Return on Equity (-1.1%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 00:32
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hapvida Participações e Investimentos S.A. is covered by 20 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Fred MendesBofA Global Research
Flavio YoshidaBofA Global Research
Frederico MendesBradesco S.A. Corretora de Títulos e Valores Mobiliários